Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 10
2006 45
2007 105
2008 132
2009 209
2010 303
2011 338
2012 386
2013 443
2014 494
2015 603
2016 607
2017 562
2018 561
2019 578
2020 605
2021 664
2022 575
2023 433
2024 133

Text availability

Article attribute

Article type

Publication date

Search Results

6,626 results

Results by year

Filters applied: . Clear all
Page 1
New Anti-VEGF Drugs in Ophthalmology.
Campa C. Campa C. Curr Drug Targets. 2020;21(12):1194-1200. doi: 10.2174/1389450121666200428101738. Curr Drug Targets. 2020. PMID: 32342814 Review.
., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail....
., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trial …
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
Cai S, Bressler NM. Cai S, et al. Curr Opin Ophthalmol. 2017 Nov;28(6):636-643. doi: 10.1097/ICU.0000000000000424. Curr Opin Ophthalmol. 2017. PMID: 28837425 Review.
At 2 years, aflibercept remained superior, on average, to bevacizumab, but not ranibizumab, among eyes with baseline visual acuity of 20/50 to 20/320. Over 2 years, in post-hoc area-under-the-curve analysis, aflibercept vision outcomes were superior to bevacizumab or ra …
At 2 years, aflibercept remained superior, on average, to bevacizumab, but not ranibizumab, among eyes with baseline visual acuity of …
Reply.
Bontzos GC, Bagheri S, Ioanidi LD, Kim IK, Datseris I, Kabanarou SA, Gragoudas ES, Miller JW, Tsilimbaris M, Vavvas DG. Bontzos GC, et al. Ophthalmol Retina. 2021 Mar;5(3):e4. doi: 10.1016/j.oret.2020.11.014. Ophthalmol Retina. 2021. PMID: 33678432 No abstract available.
Reply.
Campochiaro PA, Maass KF, Singh N, Barteselli G. Campochiaro PA, et al. Ophthalmology. 2019 Nov;126(11):e88-e89. doi: 10.1016/j.ophtha.2019.06.020. Ophthalmology. 2019. PMID: 31635711 No abstract available.
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.
Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, Li J, Liew M, Maier R, Zhu Q, Marlow N. Stahl A, et al. Lancet. 2019 Oct 26;394(10208):1551-1559. doi: 10.1016/S0140-6736(19)31344-3. Epub 2019 Sep 12. Lancet. 2019. PMID: 31522845 Clinical Trial.
INTERPRETATION: Between Dec 31, 2015, and June 29, 2017, 225 participants (ranibizumab 0.2 mg n=74, ranibizumab 0.1 mg n=77, laser therapy n=74) were randomly assigned. ...One infant had an unfavourable structural outcome following ranibizumab 0.2 mg, compare …
INTERPRETATION: Between Dec 31, 2015, and June 29, 2017, 225 participants (ranibizumab 0.2 mg n=74, ranibizumab 0.1 mg n=77, l …
Reply.
Beaulieu WT, Bressler NM, Gross JG; Diabetic Retinopathy Clinical Research Network. Beaulieu WT, et al. Am J Ophthalmol. 2017 May;177:233. doi: 10.1016/j.ajo.2017.02.010. Epub 2017 Mar 11. Am J Ophthalmol. 2017. PMID: 28292461 No abstract available.
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM. Woo SJ, et al. JAMA Ophthalmol. 2021 Jan 1;139(1):68-76. doi: 10.1001/jamaophthalmol.2020.5053. JAMA Ophthalmol. 2021. PMID: 33211076 Free PMC article. Clinical Trial.
RESULTS: Baseline and disease characteristics among 705 randomized participants (403 women [57.2%]; mean [SD] age, 74.1 [8.5] years) were comparable between treatment groups (SB11, 351; ranibizumab, 354). Least-squares mean (SE) changes in BCVA from baseline at week 8 were …
RESULTS: Baseline and disease characteristics among 705 randomized participants (403 women [57.2%]; mean [SD] age, 74.1 [8.5] years) were co …
Ranibizumab for myopic choroidal neovascularization.
Ng DSC, Fung NSK, Yip FLT, Lai TYY. Ng DSC, et al. Expert Opin Biol Ther. 2020 Dec;20(12):1385-1393. doi: 10.1080/14712598.2021.1830969. Epub 2020 Oct 12. Expert Opin Biol Ther. 2020. PMID: 33003962 Review.
Cost-effective analysis has shown that ranibizumab therapy is a cost-effective treatment for myopic CNV. Among the currently available anti-VEGF agents, ranibizumab is the only drug that is approved for the treatment of myopic CNV by the US Food and Drug Administrat …
Cost-effective analysis has shown that ranibizumab therapy is a cost-effective treatment for myopic CNV. Among the currently availabl …
Ranibizumab: A Review in Retinopathy of Prematurity.
Lee A, Shirley M. Lee A, et al. Paediatr Drugs. 2021 Jan;23(1):111-117. doi: 10.1007/s40272-020-00433-z. Epub 2021 Jan 15. Paediatr Drugs. 2021. PMID: 33447937 Review.
In the pivotal, randomized, phase III RAINBOW trial in infants with ROP, the majority of intravitreal ranibizumab recipients experienced treatment success at 24 weeks, with a numerically greater treatment success rate in the ranibizumab 0.2 mg (80% of patients) than …
In the pivotal, randomized, phase III RAINBOW trial in infants with ROP, the majority of intravitreal ranibizumab recipients experien …
Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration.
Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Khachigian LM, et al. J Transl Med. 2023 Feb 21;21(1):133. doi: 10.1186/s12967-023-03937-7. J Transl Med. 2023. PMID: 36810060 Free PMC article. Review.
Anti-vascular endothelial growth factor (VEGF) agents, such as ranibizumab, bevacizumab, aflibercept, brolucizumab and faricimab have revolutionized the clinical management of nAMD. ...
Anti-vascular endothelial growth factor (VEGF) agents, such as ranibizumab, bevacizumab, aflibercept, brolucizumab and faricimab have …
6,626 results